Nkcfo LLC Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Nkcfo LLC purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 275 shares of the biotechnology company’s stock, valued at approximately $43,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Principal Securities Inc. bought a new position in Sarepta Therapeutics during the fourth quarter worth $26,000. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at about $28,000. Riggs Asset Managment Co. Inc. grew its position in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the last quarter. Innealta Capital LLC acquired a new stake in Sarepta Therapeutics during the second quarter worth about $31,000. Finally, New Covenant Trust Company N.A. bought a new position in Sarepta Therapeutics in the first quarter worth about $32,000. 86.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Citigroup dropped their price objective on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. UBS Group upped their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $235.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. Finally, Barclays lowered their target price on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $187.39.

Sarepta Therapeutics Trading Up 0.1 %

Shares of SRPT opened at $127.21 on Friday. The business’s 50-day moving average price is $137.26 and its 200 day moving average price is $132.60. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $12.02 billion, a P/E ratio of 1,156.45 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same quarter in the prior year, the firm earned ($0.27) EPS. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. Analysts expect that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now owns 17,129 shares in the company, valued at approximately $2,768,217.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the transaction, the executive vice president now directly owns 17,129 shares in the company, valued at approximately $2,768,217.69. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,801 shares of company stock worth $8,399,586. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.